Mangoceuticals, Inc.
Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 06 Feb 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Annual report filed late (NT 10-K)
The company filed Form NT 10-K with the SEC on 31 Mar 2026, notifying investors that its annual report would be late. A late annual report can point to accounting or audit problems, though the reason is sometimes routine.
More details →Quarterly report filed late (NT 10-Q)
The company filed Form NT 10-Q with the SEC on 15 May 2026, notifying investors that its quarterly report would be late. Late filings can point to accounting or business problems, though the reason is sometimes routine.
More details →Mangoceuticals, Inc. — Overview & Financial Snapshot
Mangoceuticals, Inc. (NasdaqCM: MGRX) is a Healthcare company, ranked #2,384 of 6,774 companies globally and #746 of 4,000 in United States on PositoAI, with a Positivity Score of 21,576. Its market capitalisation is ₹51.25 Cr ($5.43M), P/E ratio is -0.2 and P/B ratio is 0.43. It currently has 1 active red flag (PosiRed) and 2 yellow flags (PosiYellow, 6/10 points) on record.
For financial statements, ratio trends and score history, Go Deep →